Bionano Genomics (NASDAQ: BNGO) is a genomics instrumentation company that develops and sells optical genome mapping (OGM) systems for structural variant detection in human DNA. Revenue comes from two streams: product sales of instruments and consumables, and service and other revenue. Product revenue was $26.7M (FY2025) and $27.0M (FY2024), while service and other revenue was $1.8M (FY2025) and $3.8M (FY2024), for total revenue of $28.5M (FY2025) and $30.8M (FY2024). The company sells its Saphyr and Stratys OGM instruments globally, with EMEA as the largest region at 49.5% of FY2025 revenue ($14.1M), Americas at 42.7% ($12.2M), and Asia Pacific at 7.8% ($2.2M). CEO R. Erik Holmlin, Ph.D. serves as President and Chief Executive Officer, with Mark Adamchak as VP of Accounting and Principal Accounting Officer. The company uses contract manufacturers to produce its instruments.

Revenue model

Transactional product sales of OGM instruments (Saphyr, Stratys) and consumables (Saphyr Chip), plus service and other revenue from laboratory diagnostic processing, warranty services, and equipment servicing. Product revenue was 93.8% of total revenue in FY2025 ($26.7M of $28.5M). Software upgrades are periodically made available to customers via download.

Products and services

Saphyr OGM instrument: capable of analyzing up to 4,000 human genomes per year at 100x coverage, imaging DNA at approximately 205 Gbp per hour. Stratys OGM instrument: higher-throughput system capable of analyzing up to 13,500 human genomes per year at 100x coverage, imaging between 530 and 820 Gbp per hour, designed for medium and high-volume labs, with up to 4x the throughput of Saphyr. Saphyr Chip: the consumable used in the Saphyr system. OGM systems use fluorescent labeling of sequence-specific sites on long DNA fragments imaged in nanochannels to detect structural variants. Systems have demonstrated up to 75% reduction in turnaround time versus karyotyping, FISH, and MLPA for acute lymphoblastic leukemia analysis.

Customers and end markets

Customers include medium and high-volume genomics laboratories. End markets include clinical cytogenetics (acute lymphoblastic leukemia referenced specifically), research genomics, and diagnostic labs processing structural variant analysis. Geographic customer base spans Americas, EMEA, and Asia Pacific (including China, Japan, South Korea, Singapore, India, and Australia).

Value-chain role

Instrument and consumable manufacturer positioned as a capital equipment and reagent supplier to genomics laboratories. Uses contract manufacturers for production. Competes at the point of laboratory workflow, replacing or supplementing karyotyping, FISH, and MLPA techniques.

Geographic exposure

EMEA: 49.5% of FY2025 revenue ($14.1M). Americas: 42.7% ($12.2M). Asia Pacific: 7.8% ($2.2M). All figures from the year ended December 31, 2025.

Source: SEC 10-K, filed 2026-03-23

Industry: Laboratory Analytical Instruments Peers: Adaptive Biotechnologies Corp Akoya Biosciences, Inc. Neogenomics Inc Inotiv Inc SomaLogic, Inc. Codexis Inc MaxCyte Inc NS Wind Down Co., Inc. Seer, Inc. Thermo Fisher Scientific Inc